[go: up one dir, main page]

WO2003022858A3 - Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu - Google Patents

Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu Download PDF

Info

Publication number
WO2003022858A3
WO2003022858A3 PCT/EP2002/010140 EP0210140W WO03022858A3 WO 2003022858 A3 WO2003022858 A3 WO 2003022858A3 EP 0210140 W EP0210140 W EP 0210140W WO 03022858 A3 WO03022858 A3 WO 03022858A3
Authority
WO
WIPO (PCT)
Prior art keywords
domain
protein
inhibitors
screening
hairpin ribozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/010140
Other languages
English (en)
French (fr)
Other versions
WO2003022858A2 (de
Inventor
Seyed Hani Najafi-Shoushtari
Joerg Hartig
Michael Famulok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NascaCell GmbH
Original Assignee
NascaCell GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10144647A external-priority patent/DE10144647A1/de
Application filed by NascaCell GmbH filed Critical NascaCell GmbH
Priority to AU2002342672A priority Critical patent/AU2002342672A1/en
Publication of WO2003022858A2 publication Critical patent/WO2003022858A2/de
Publication of WO2003022858A3 publication Critical patent/WO2003022858A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft in einem Aspekt ein allosterisch regulierbares Hairpin-Ribozym. ln einem zweiten Aspekt betrifft die Erfindung ein Polynukleotid umfassend ein Hairpin-Ribozym, wobei das Hairpin-Ribozym mindestens eine substratbindende Domäne A und eine Domäne B umfasst, wobei bei Kontakt der Domäne B mit der Domäne A die katalytische Aktivität begründet wird und zwischen Domäne A und Domäne B eine Domäne C angeordnet ist, wobei die Domäne C die Domänen A und B verbindet und eine ein Zielmolekül bindende Nukleinsäure umfasst. ln einem dritten Aspekt betrifft die Erfindung ein Polynukleotid umfassend ein Hairpin-Ribozym, wobei das Hairpin-Ribozym mindestens eine substratbindende Domäne A und eine katalytische Domäne B umfasst, wobei bei Kontakt der Domäne B mit der Domäne A die katalytische Aktivität begründet wird, wobei zwischen Domäne A und Domäne B eine Domäne C angeordnet ist und die Domäne C die Domänen A und B verbindet und eine zu einer ein Zielmolekül bindenden Nukleinsäure zumindest teilweise komplementäre Nukleinsäure umfasst.
PCT/EP2002/010140 2001-09-11 2002-09-10 Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu Ceased WO2003022858A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002342672A AU2002342672A1 (en) 2001-09-11 2002-09-10 Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10144647A DE10144647A1 (de) 2001-09-11 2001-09-11 Verfahren zum Screenen von Inhibitoren für die Wechselwirkung zwischen Nukleinsäuren und Interaktoren sowie Robozyme hierzu
DE10144647.0 2001-09-11
DE10229393.7 2002-06-29
DE10229393 2002-06-29

Publications (2)

Publication Number Publication Date
WO2003022858A2 WO2003022858A2 (de) 2003-03-20
WO2003022858A3 true WO2003022858A3 (de) 2003-08-28

Family

ID=26010109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010140 Ceased WO2003022858A2 (de) 2001-09-11 2002-09-10 Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu

Country Status (2)

Country Link
AU (1) AU2002342672A1 (de)
WO (1) WO2003022858A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2497047A1 (en) * 2002-08-27 2004-03-11 Compound Therapeutics, Inc. Adzymes and uses thereof
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
EP2799448A1 (de) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Polyvalente Proteine mit Fibronectin-Gerüstdomänen
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2576615B1 (de) 2010-05-26 2016-03-30 Bristol-Myers Squibb Company Auf fibronectin basierende gerüstproteine mit erhöhter stabilität
WO2015143199A1 (en) 2014-03-20 2015-09-24 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
EP3708580B1 (de) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Schnell ablaufende serumalbuminbindende fibronektin-typ-iii-domänen

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0277096A2 (de) * 1987-01-28 1988-08-03 Warner-Lambert Company Thrombin-Zubereitungen
US4959212A (en) * 1988-06-22 1990-09-25 Alexandra Stancesco Oxidizing-energizing composition and method for the treatment of diabetes
EP0468327A2 (de) * 1990-07-23 1992-01-29 Iketon Farmaceutici S.R.L. Hirudin enthaltende orale Arzneimittel
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
WO2002042491A2 (de) * 2000-11-22 2002-05-30 Nascacell Gmbh Verfahren zur identifizierung von verbindungen oder leitstrukturen gegen rna-target-motive und rna/protein wechselwirkungen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0277096A2 (de) * 1987-01-28 1988-08-03 Warner-Lambert Company Thrombin-Zubereitungen
US4959212A (en) * 1988-06-22 1990-09-25 Alexandra Stancesco Oxidizing-energizing composition and method for the treatment of diabetes
EP0468327A2 (de) * 1990-07-23 1992-01-29 Iketon Farmaceutici S.R.L. Hirudin enthaltende orale Arzneimittel
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
WO2002042491A2 (de) * 2000-11-22 2002-05-30 Nascacell Gmbh Verfahren zur identifizierung von verbindungen oder leitstrukturen gegen rna-target-motive und rna/protein wechselwirkungen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ESTEBAN ET AL.: "Structural basis for heterogeneous kinetics: Reengineering the hairpin ribozyme", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE US, vol. 95, May 1998 (1998-05-01), pages 6091 - 6096, XP002234998 *
FAMULOK M: "OLIGONUCLEOTIDE APTAMERS THAT RECOGNIZE SMALL MOLECULES", CURRENT OPINION IN STRUCTURAL BIOLOGY, CURRENT BIOLOGY LTD., LONDON, GB, vol. 9, no. 3, 1999, pages 324 - 329, XP001031183, ISSN: 0959-440X *
KOMATSU ET AL.: "In vitro selection of hairpin ribozymes activated with short oligonucleotides", BIOCHEMISTRY, vol. 41, 23 July 2002 (2002-07-23), pages 9090 - 9098, XP002235000 *
ROBERTSON MICHAEL P ET AL: "Design and optimization of effector-activated ribozyme ligases", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 28, no. 8, 15 April 2000 (2000-04-15), pages 1751 - 1759, XP002205328, ISSN: 0305-1048 *
SOUKUP GARRETT A ET AL: "Engineering precision RNA molecular switches", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 7, 30 March 1999 (1999-03-30), pages 3584 - 3589, XP002158536, ISSN: 0027-8424 *
WALTER ET AL.: "Stability of hairpin ribozyme tertiary structure is governed by the interdomain junction", NATURE STRUCTURAL BIOLOGY, vol. 6, no. 6, 1999, pages 544 - 549, XP002234999 *

Also Published As

Publication number Publication date
AU2002342672A1 (en) 2003-03-24
WO2003022858A2 (de) 2003-03-20

Similar Documents

Publication Publication Date Title
WO2003062462A3 (en) Method for isolating nucleic acids and protein from a single sample
WO1999016871A3 (en) Nucleic acid catalysts with endonuclease activity
ZA981762B (en) Nucleic acid molecules encoding enzymes having fructosyl polymerase activity.
WO2003022858A3 (de) Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu
WO2003054177A3 (de) Neue glykosylhydrolasen
WO2000008196A3 (en) Urate oxidase
WO2003006652A3 (en) Inhibition of specific histone deacetylase isoforms
WO2005042716A3 (en) Nucleic acid binding oligonucleotides
WO2005003291A3 (en) Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
ATE479759T1 (de) Nukleinsäuren, die für enzyme aus weizen kodieren,welche an der stärkesynthese beteiligt sind
WO2002004488A3 (en) Nucleic acid binding polypeptides
WO1998043993A3 (en) Nucleic acid catalysts
WO1998008974A3 (en) Catalytic nucleic acid and its medical use
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003097810A3 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
WO2002050285A3 (en) Histone deacetylase-related gene and protein
HK1049185A1 (zh) 可改萤光蛋白
WO2005097205A3 (en) Dna virus microrna and methods for inhibiting same
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
WO2000028043A3 (en) Polypeptides having lactonohydrolase activity and nucleic acids encoding same
WO2000058352A3 (en) Barley gene for thioredoxin and nadp-thioredoxin reductase
WO2000079263A3 (en) Identifying active molecules using physico-chemical parameters
WO2003050265A3 (en) Compositions and methods for normalizing assays
WO2000017346A3 (en) Hairpin hybridizer molecules for modulation of gene expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP